Efficacy and safety of the weight-loss drug rimonabant

The Lancet

Volumn 371, Issue 9612, 2008, Pages 555-556

  Blüher, Matthias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIMONABANT; ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; EUROPE; HUMAN; LETTER; MOOD DISORDER; PRIORITY JOURNAL; RISK FACTOR; WEIGHT REDUCTION; MAJOR DEPRESSION; NOTE; OBESITY; PSYCHOLOGICAL ASPECT;

ANTI-OBESITY AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 38949148213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60262-7     Document Type: Letter

References (5)

1. Christensen R., Kristensen P., Bartels E., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
2. Rucker D., Padwal R., Li S., Curioni C., and Lau D. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007). doi:10.1136/bmj.39385.413113.25
3. European Medicines Agency. Acomplia: summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/H-666-PI-en.pdf (accessed Nov 21, 2007).
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Association, Washington, DC
5. US Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee Meeting (June 13, 2007). http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-00-index.htm (accessed Jan 25, 2008).